Moderna

Moderna plans a $2B convertible note offering; AstraZeneca-Amgen Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power…

ENDPOINTS · 2026-08-27

Plus news about Takeda China and ProFound. Moderna's $2B offering: The mRNA biotech will offer convertible senior notes for the "flexibility to invest" in growing its oncology business and repay debt ...

Source: Endpoints News